Research for Pheast Therapeutics to Present Preclinical Data on PHST001, a First-in-class Antibody Targeting CD24, at the Society for Immunotherapy of Cancer (SITC) 2026 Annual Meeting - aVenture Research
BioSpace
Pheast Therapeutics to Present Preclinical Data on PHST001, a First-in-class Antibody Targeting CD24, at the Society for Immunotherapy of Cancer (SITC) 2026 Annual Meeting
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Pheast Therapeutics, a clinical-stage biotechnology company advancing next-generation targeted therapies for cancer, today announced an upcoming poster presentation of preclinical data on PHST001 at the 41st Society for Immunotherapy of Cancer (SITC) Annual Meeting, taking place from November 4-8 in Phoenix, AZ. PHST001 is a first-in-class anti-CD24 macrophage checkpoint inhibitor designed to restore immune recognition in the tumor microenvironment and is c